Revvity, Inc. (RVTY) is a Massachusetts-based life sciences and diagnostics company formed in 2023. It provides instruments, reagents, software, informatics, and testing platforms used by pharmaceutical and biotech firms, research institutions, clinical labs, public health organizations and governments to support genetic screening, infectious disease testing, biomarker discovery, multi-omics science, and broader life sciences workflows. It is currently valued at $11.1 billion by market cap. The healthcar ...

With a market cap of $9.1 billion, Bio-Techne Corporation (TECH) is a global life sciences company that develops, manufactures, and sells reagents, instruments, and services for research, diagnostics, and bioprocessing markets. The company operates through two segments: Protein Sciences and Diagnostics and Spatial Biology. Companies valued less than $10 billion are generally classified as “mid-cap” stocks, and Bio-Techne fits this criterion perfectly. The company’s offerings support applications ranging ...

Core Thesis - Bio-Techne Corporation is positioned as a global leader in life-science consumables and specialized tools, with a strong focus on research, diagnostics, and emerging therapies [2][3] Company Overview - Founded in 1976, Bio-Techne has undergone strategic pivots and acquisitions, currently led by CEO Kim Kelderman and CFO Jim Hippel [2] - The company operates with a performance-aligned compensation framework and has broad analyst coverage [2] Revenue Generation - Bio-Techne generates most of its revenue from high-quality, premium-priced consumables, holding a 30-40% market share in cytokines and growth factors, approximately 5% in antibodies, and a leadership position in cited proteins [3] - The product portfolio includes reagents, assays, instruments, and proprietary platforms, primarily sold direct-to-consumer with distributor partnerships, notably with Thermo Fisher [3] Market Position and Growth - Despite intense competition, Bio-Techne's premium brand, scale advantages, and diverse applications support its market share growth in precision medicine, biologics, and spatial biology [4] - The company has launched 800 new products in 2024 and expanded its total addressable market (TAM) from $3 billion to approximately $28 billion since 2013 [4] Financial Strength - Bio-Techne maintains solid financial strength with conservative leverage, strong free cash flow, and capacity for further acquisitions [5] - Current valuation reflects compressed multiples and cautious sentiment rather than a decline in fundamentals, indicating a compelling investment opportunity [5] Historical Performance - The stock price has appreciated approximately 34.8% since May 2025, driven by improved demand trends and solid core franchises [6] - The long-term TAM expansion is emphasized as a key factor for continued growth [6]

Core Insights - The CEO of Avantor, Emmanuel Ligner, demonstrated confidence in the company's stock by purchasing 87,500 shares, increasing his direct ownership to 283,424 shares, reflecting a bullish outlook on the stock's potential [1][9]. Transaction Summary - The transaction involved 87,500 shares traded at a value of $993,125, with a post-transaction ownership of 283,424 shares valued at approximately $3,083,653 based on the trade-date close price of $10.88 [2][6]. Company Overview - Avantor employs 13,500 individuals and reported a total revenue of $6.58 billion with a net income loss of $82.20 million over the trailing twelve months [4]. - The company's stock experienced a significant decline of 43.42% over the past year as of the transaction date [4]. Impact of the Purchase - The purchase increased Ligner's direct holdings by 44.66%, raising his ownership stake to 0.0416% of total shares outstanding [6]. - This transaction is noted as the largest reported trade for Ligner, both in terms of share count and percentage increase in direct holdings [6]. Company Profile - Avantor provides a wide range of high-purity materials, reagents, laboratory supplies, and specialty procurement services across various sectors, including biopharma, healthcare, and advanced technology [7][8]. - The company generates revenue primarily through consumables, customized materials, and laboratory equipment, along with value-added services [7]. Recent Performance and Outlook - Following a 52-week low of $10.83, Ligner's purchase suggests a positive outlook, coinciding with Avantor's initiation of a $500 million stock repurchase program [9]. - The company faced challenges in Q3, with a 5% year-over-year revenue decline to $1.62 billion and a significant goodwill impairment charge of $785 million, resulting in a net loss of $711.8 million [10].

Core Insights - Cullen Capital Management's "SCCM Value Equity Strategy" reported a gross return of 6.9% and a net return of 6.8% for Q3 2025, outperforming the Russell 1000 Value's 5.3% and underperforming the S&P 500's 8.1% during the same period [1] - Year-to-date, the strategy achieved a gross return of 13.0%, compared to Russell 1000 Value's 11.7% and S&P 500's 14.8% [1] Company Overview - Becton, Dickinson and Company (NYSE: BDX) is a global medical technology company that develops and manufactures a wide range of medical supplies, devices, laboratory equipment, and diagnostic products [2][3] - The company has three main segments: BD Medical (50% of 2024 sales), BD Life Sciences (26%), and BD Interventional (24%) [3] - BD Medical focuses on medication delivery devices, holding over 80% market share in US hospital syringes, making it the largest manufacturer of syringes globally [3] Stock Performance - Becton, Dickinson and Company's stock had a one-month return of 2.24% but lost 13.52% over the last 52 weeks, closing at $192.33 per share on November 18, 2025, with a market capitalization of $55.127 billion [2]

Financial Highlights - Total revenue for Q3 2025 was $700 million, a decrease of 5% year-over-year on a constant currency basis[5] - Adjusted EBITDA for Q3 2025 was $177 million, representing a 25% margin[5] - Adjusted diluted EPS for Q3 2025 was $080, a decrease of 6% year-over-year[6] - Year-to-date 2025 total revenue was $201 billion, a decrease of 3% year-over-year on a constant currency basis[11] - Year-to-date 2025 adjusted EBITDA was $444 million, representing a 22% margin[11] - Year-to-date 2025 adjusted diluted EPS was $166, an increase of 36% year-over-year[11] Revenue Breakdown - Recurring revenue accounted for 82% of total revenue in Q3 2025[7] and 84% year-to-date[10] - North America accounted for 57% of revenue in Q3 2025[7] and 58% year-to-date[10] - Labs business unit contributed 51% of revenue in both Q3 2025 and year-to-date 2025[7, 10] Financial Guidance - The company projects full-year 2025 revenues to be between $268 billion and $274 billion[22] - The company anticipates an adjusted EBITDA margin of 22% for full-year 2025[22]

Core Insights - Bio-Techne Corporation reported a 1% decrease in net sales for the first quarter of fiscal 2026, totaling $286.6 million, with organic revenue also down by 1% compared to the previous year [6][9][30] - The company experienced a 19% increase in GAAP operating income, reaching $47.7 million, and a GAAP EPS of $0.24, up from $0.21 in the same quarter last year [7][21] - Adjusted operating margin improved to 29.9%, reflecting ongoing productivity and cost containment initiatives [10][24] Financial Performance - Net sales decreased by 1% to $286.6 million, with organic revenue also down by 1%, influenced by a favorable foreign currency impact of 1% and an unfavorable impact from businesses held-for-sale [6][9] - GAAP operating income increased by 19% to $47.7 million, with an operating margin of 16.6%, up from 13.8% in the prior year [7][24] - Adjusted EPS remained stable at $0.42, while adjusted operating income rose to $84.2 million from $83.2 million [10][28] Segment Performance - The Protein Sciences segment reported net sales of $202.2 million, a decrease of 1% from $204.5 million in the prior year, with an operating margin of 38.4% [12][29] - The Diagnostics and Spatial Biology segment saw net sales of $79.5 million, down 4% from $83.2 million, but achieved organic revenue growth of 3% [13][29] - The overall operating income for the segments combined was $86.6 million, with a notable increase in the operating margin for the Diagnostics and Spatial Biology segment to 11.2% from 5.1% [31] Strategic Initiatives - The company completed the divestiture of its Exosome Diagnostics business to focus on non-CLIA based product lines, aligning with its growth strategy [9][10] - Bio-Techne's leadership expressed optimism regarding the stabilization of the US academic end market and continued strength from large pharmaceutical customers [3][9] - The company is positioned to leverage its differentiated portfolio of advanced life science tools and reagents to drive long-term value [3][10]

Group 1 - Thermo Fisher Scientific Inc. is recognized as a strong long-term low volatility stock, with a Buy rating reiterated by Bank of America Securities analyst Michael Ryskin [1] - The company announced plans to expand its growth strategy through collaboration with OpenAI, aiming to enhance drug development speed and cost-effectiveness [2] - The collaboration with OpenAI focuses on accelerating scientific innovation, improving productivity, and simplifying operations by integrating OpenAI APIs into various business areas [3] Group 2 - Thermo Fisher Scientific provides a range of analytical instruments, reagents, equipment, software, and services across multiple segments, including Analytical Instruments and Life Sciences Solutions [4]

Group 1 - Thermo Fisher Scientific Inc. (NYSE:TMO) is considered one of the best medical stocks to buy currently, with analysts from Bank of America Securities and Bernstein reiterating Buy ratings and setting price targets of $560.00 and $570.00 respectively [1][2] - Barclays upgraded Thermo Fisher Scientific Inc. from Equal Weight to Overweight on September 11, raising its price target from $490 to $550 [2] - The company provides a range of products and services including analytical instruments, reagents, equipment, software, and services for analysis, research, diagnostics, and discovery, operating through various segments [3]

Company Overview - Revvity, Inc. (RVTY) has a market capitalization of $10 billion and is a global provider of health sciences solutions, technologies, and services, offering a wide range of products including instruments, reagents, informatics, software, imaging technologies, DNA sequencing services, and diagnostic platforms for genetic and infectious disease testing [1][2] Stock Performance - Revvity's shares have decreased by 33.1% from their 52-week high of $129.50 and have fallen 8.8% over the past three months, underperforming the Health Care Select Sector SPDR Fund (XLV), which gained 3.7% during the same period [3] - Year-to-date, RVTY stock is down 22.4%, while XLV has experienced a marginal drop. Over the past 52 weeks, Revvity shares have decreased by 29.1%, compared to XLV's 11.2% decline [4] Financial Forecast - On July 28, Revvity's shares fell 8.3% after the company revised its full-year adjusted profit forecast to $4.85 to $4.95 per share, citing weaker demand in China, where diagnostic product sales declined by double digits in Q2 2025 due to new reimbursement policies [5] - The company now expects diagnostics sales growth to be in the low single digits, down from an earlier forecast of mid-single digits [6] Analyst Sentiment - Despite the weak stock performance, analysts maintain a moderately optimistic outlook for Revvity, with a consensus rating of "Moderate Buy" from 18 analysts and a mean price target of $114.62, representing a 33.7% premium to current levels [7]